Clinical Trial

A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants

Name: A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants — clinical trial record (NCT07439510)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This Phase 2b/3, randomized, double-blind, placebo-controlled, 2-part study will evaluate the efficacy, safety and tolerability of different dose regimens of SPG601 in adult male participants with Fragile X syndrome.

Trial Details

NCT Number	NCT07439510
Lead Sponsor	Spinogenix
Conditions	Fragile X Syndrome (FXS)
Enrollment	248 participants
Start Date	2026-03-01
Primary Completion	2030-02-01 (estimated)
Study Completion	2030-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-27